verified99%+ Verified Purity
local_shippingFast EU Delivery (through resellers)
Myotrope
Homechevron_rightAll Peptideschevron_rightTirzepatide Injection Pen 3ml
Tirzepatide Injection Pen 3ml
verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-tirzepatide-injection-pen-3ml-10mg-3ml

Official Product Data Sheet

Tirzepatide Injection Pen 3ml (10mg/3ml)

High >98% Purity

Vial Contents
10 mg Tirzepatide (3 mL pre-filled injection pen)
Includes
Ready-to-use multi-dose injection pen — no mixing required
Form
Pre-filled 3 mL multi-dose pen
Purity
≥98%, third-party verified
Sequence
Dual GIP/GLP-1 Agonist
Molecular Formula
See chemical properties
Molecular Mass
≈4813 g/mol
CAS No.
2023788-19-2
Solubility
Concentration: ≈3.33 mg/mL | Per click: 1 unit ≈ 33.33 mcg (0.033 mg)
Storage
Refrigerate at 2–8 °C. Protect from light. Do not freeze.

Authorized Resellers

Available through our trusted partners

12
verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
DE
verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
View all authorized resellersshopping_cart
swipe_rightSwipe to see all tabs

Scientific Background

Tirzepatide is a dual GIP and GLP-1 receptor agonist providing simultaneous incretin pathway activation for superior metabolic research outcomes. This 3 mL format contains 10 mg at ≈3.33 mg/mL, providing the same dosing economics as the standard 10 mg pen with extended dosing flexibility for research protocols.

Intended Research Use

  • Dual incretin (GIP + GLP-1) receptor activation research
  • Extended duration metabolic studies
  • Dose-response and titration protocols
  • Appetite suppression and body composition research

menu_bookScientific Publications

article

N Engl J Med (2022)

Tirzepatide Once Weekly for the Treatment of Obesity

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35665733/

article

N Engl J Med (2021)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34170647/

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Myotrope

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Tirzepatide pairs with complementary fat loss and metabolic peptides.

Cagrilintide 5mg

Cagrilintide 5mg (5mg vial)

arrow_forward

myo-cagrilintide-5mg

Additive satiety — Cagrilintide's amylin analog complements Tirzepatide's dual incretin action for comprehensive appetite control.

AOD-9604 5mg

AOD-9604 5mg (5mg vial)

arrow_forward

myo-hgh-fragment-aod-9604-5mg

Targeted lipolysis alongside systemic metabolic improvement from Tirzepatide.

schedule

Cycling Note: Typical protocol: 12–52 weeks with gradual titration every 4 weeks.

Also Available

Tirzepatide 10mg
Vial

Tirzepatide

10mg

Tirzepatide 15mg
Vial

Tirzepatide

15mg

Tirzepatide 30mg
Vial

Tirzepatide

30mg

Tirzepatide 60mg
Vial

Tirzepatide

60mg

Tirzepatide Injection Pen 10mg
Pen

Tirzepatide Injection Pen

10mg